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There is growing evidence to suggest a role for the T  cell lymphokine gamma 
interferon (IFN-3') in the regulatory biology of cells of the monocyte/macrophage 
lineage.  IFN-3,  induces  differentiation  of  immature  myeioid  cells  along  the 
monocytic pathway and induces or enhances expression of class II HLA antigens 
during this process (1). Upon exposure to IFN-3,, immature and mature mono- 
cytic  cells  acquire  tumoricidal  activity  (2)  and  expres~  new  receptors  for  Fc 
fragments  that  bind antibody-coated particles,  and  so initiate phagocytosis.  In 
addition, IFN-~, inhibits monocyte migration in a manner similar to macrophage 
migration inhibitory factor (3), and inhibits growth of myeloid progenitor cells, 
particularly  those  destined  to  form  granulocyte  colonies  (4).  In  the  present 
report, we show by immunofluorescence and biochemical identification that IFN- 
3'  induces  surface  expression  of receptors  for interleukin  2  (IL-2) by  normal 
human monocytes and by the monocytic and promyelocytic cell lines U937 and 
HL60. These results suggest the possible involvement of an  IL-2 receptor (IL- 
2R) system on human monocytic cells in monocyte/T cell interaction. 
Materials and Methods 
Cells Analyzed for IL-2R Expression.  Human myeloid leukemia cell lines KG1, HL60, 
U937, and  HEL were maintained in  RPMI  1640  medium with  10%  fetal calf serum. 
Mononuclear cell suspensions from acute myeloblastic leukemia (AML) and normal bone 
marrow (NBM) specimens were prepared by FicolI-Hypaque density gradient centrifuga- 
tion. NBM progenitor cells enriched 80-100-fold for myeloblasts were obtained using an 
immune rosette technique previously described (5).  Erythroid precursor cells were pre- 
pared similarly from human  fetal liver mononuclear cells.  B cell-enriched populations 
were obtained from normal spleen lymphocytes by depletion of T  cells and monocytes. 
Normal T  cells were prepared by E rosetting. Monocytes were isolated from E- cells by 
two plastic adherence steps. Granulocytes were obtained using dextran sedimentation. 
Induction oflL-2R Expression.  To induce IL-2R expression, cells were cultured at 1 × 
106 cells/ml in flat-bottom tissue culture plates (35 ×  14 mm) in the presence of 10-1,000 
U/ml of recombinant IFN-'r (kindly provided by Dr. Steven Reich, Biogen, Cambridge, 
MA) for a period of 12-96 h. 
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In selected experiments other compounds known to affect differentiation of myeloid/ 
monocytic cell lines were added for 68 h to U937 and HL60 cultures, including phyto- 
hemagglutinin (PHA) leukocyte-conditioned medium (PHA-LCM, 10% vol/vol), recom- 
binant alpha IFN (500  U/mi) (Hoffman-La Roche, Inc., Nutley, NJ), prostaglandin E2 
(10 -6 M), retinoic acid (10 -6 M), dimethyl sulfoxide (DMSO)  (1.1%  vol/vol), 1,25(OH)2 
vitamin D3  (10 -s  M) (Hoffman-La Roche, Inc.), and cAMP (10 -3 M) (Sigma Chemical 
Co., St. Louis, MO). 
Monoclonal Antibodies.  Anti-TAC (6) antibody was a gift from Dr. T. Waldmann. All 
other antibodies used were produced in the Division of Tumor Immunology, including 
anti-T3, -T11, -T9, -B1, -B4, and -HLA-DR (9-49),  MY4, Mo2, and anti-IL-2R1. The 
characterization of these antibodies has been previously reviewed (7). 
Immunofluorescence Staining.  For one-color staining, 1 ×  106 cells were incubated for 
30 min at 4°C with the appropriate monoclonal antibody or irrelevant isotype-identical 
control antibody. If antibodies were not directly fluorescein conjugated, a second incu- 
bation was performed for 30 min at 4°C with fluorescein-conjugated goat anti-mouse Ig 
(Tago, Inc., Burlingame, CA). Washing medium contained 10% human AB serum. 
For dual fluorescence studies, IFN-7-treated monocytes were incubated with biotin- 
conjugated anti-Mo2 and a  fluoresceinated anti-IL-2Rl  (8). After washing, cells  were 
developed with avidin-conjugated Texas Red (Molecular Probes, Junction City, OR). Cells 
were analyzed using a dual laser flow cytometer (EPICS  V; Coulter Electronics, Hialeah, 
FL). 
lodination, Immunoprecipitation, and SDS-PAGE.  U937 cells treated for 60 h with 500 
U/ml IFN-3, were externally labeled with 1~5I using the lactoperoxidase-catalyzed method 
(10).  lmmunoprecipitates with anti-TAC  antibody were  analyzed by sodium dodecyl 
sulfate- 10% polyacrylamide gel electrophoresis (SDS-PAGE). 
Effect of Recombinant IL-2 (rlL-2) on IFN-3,-primed U937 Cells.  To determine whether 
rlL-2R bound to induced IL-2R, the proliferative response of rlFN-~,  primed U937 to 
rlL-2 was tested. U937 cells (1  x  106/ml)  were cultured in the presence of 500  U/ml 
rIFN-7  (concentration of IFN-~, was  determined by  Biogen).  After  48  h,  cells  were 
harvested  by vigorous pipetting,  transferred  to  96-well,  round-bottom plates  (Linbro 
Chemical Co., Hamden, CT) and cultured for another 48 h in the presence of various 
dilutions (100, 500,  1,000  U/ml) of rlL-2 at 5 x  104 cells/ml. 12 h before cell harvest 
some of the cultures were pulsed with 1 ~Ci [3H]thymidine ([~H]TdR). To study adsorption 
of added rlL2 by IL-2R-expressing U937 cells, we assayed supernatants from nonpulsed 
cultures for IL-2 using IL-2-dependent T cells as described (9). The proliferative response 
to IL-2 was measured as [3H]TdR uptake. 
Results and Discussion 
IL-2 stimulates in vitro proliferation of activated T  and B cells (6,  10,  11) by 
acting  through  specific cell  membrane  receptors  that  have  been  identified as 
p60-65  antigens by anti-receptor  monoclonal antibodies (6,  8).  We show that 
not only T  and B cells but also normal human peripheral blood monocytes and 
leukemic cell lines (U937,  HL60) capable of monocytic differentiation, express 
IL-2 surface receptors when exposed to the T  cell lymphokine IFN-% 
Exposure of U937 cells to rIFN-3~  (500  U/ml) induced expression of binding 
sites  for  anti-IL-2R  antibody  24-48  h  after  initiation  of cultures  (Table  I). 
Identification of these binding sites as IL-2R was confirmed by immunoprecipi- 
tation of the same 60-65  kD protein  from surface-labeled U937  cells as from 
PHA-activated T  cells (Fig.  1). Also, rIL-2-induced U937 cells could adsorb IL- 
2  biological activity but noninduced U937  cells could not (Table  II). The time 
course of induction of IL-2R paralleled the induction of class II HLA antigens, 
suggesting de novo synthesis rather than the unmasking of cryptic receptors.  In 
a  survey of hematopoietic cells (Table  III), the induction of IL-2R by IFN was HERRMANN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Induction of lL-2R on U937 Cells 
1113 
Dose response (48 h culture) 
rl FN-~'  Anti-I L-2 R 1  ÷  Recovery* 
U/ml  % 
0  2.0 
50  17.1 
500  52.7 
250  32.6 
1,000  41.6 
Kinetics of IL-2R expression  (500 U/ml rlFN-3") 








h  %  % 
0  2.0  100 
12  7.2  96 
24  16.4  86 
48  52.7  76 
96  43.3  61 
* Percent of initial cell number in culture. 
FIGURE  1.  SDS-PAGE analysis of immunoprecipitates obtained with anti-TAC antibody on 
PHA-activated T  cells (B) and IFN-3' (48 h, 500 U/ml)-treated U937 cells (D) under reducing 
conditions.  A  and  C  represent  control  immunoprecipitates  from  the  same  cells  using  an 
unreactive control antibody (antiTglycophorin A, clone 39). 
TABLE  II 
Adsorption  of lL-2 by U937 Cells 
[SH]TdR incorporation of 
IL-2-dependent T ce~ls 
cpra 
Uninduced U937 cells*  5,100 -+ 470 
IFN-7-induced  U937 cells  200 ±  35 
* U937 cells (1  ×  106/ml) were cultured in the presence or absence of rlFN-7 for 
48  h,  washed,  and  recultured  in  fresh  medium for an additional  48  h  in  the 
presence of rlL2 (500 U/ml). Culture supernatants were then removed and assayed 
for the presence of remaining IL-2 on IL-2-dependent human T  cells. For this, T 
cells (plus 5%  macrophages) previously  cultured for 7 d  with  PHA (0.5 mg/m  0 
were recultured in 96-well plates (5 ×  104/well, 0.2  ml total volume per well) in 
the presence of 20% (vol/vol) of the supernatants. 1114  HERRMANN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE III 
Effect of rlVN-7 (48 h, 500 U/ml) on IL-2R Expression of Various Cell Types 
Leukemic cells: 
HL60  KG-I 
Percent cells stained with anti-lL-2Ri 
AML (MI,  AML (M4, 
M2)  M5) 
(n = 3)  (n = 5) 
Noninduced  1.4  64.0  0  0-1.7 
rl FN-~,  induced  37.6  63.3  0-1.3  5.7-37.6 
Granulo-  Erythroid 
Normal cells:  Monocytes  T  cells  B cells  Myeloblasts  progeni- 
cytes  tors 
Noninduced cells  0  0  0  0  0  0 
rIFN-7 induced cells  0  62.9  1.5  0  4.0  1.7 
TABLE  IV 
Effects of Various Differentiation-inducing  Compounds (48 h exposure) on Myeloid Cell Lines 
Nomreated  r I FN-"t"  rlFN-a  PHA-LCM  PGE2 
U937  HL6O  KG1  U937  HL60  KG1  U937  HL60  KG1  U937  HL60  KGI  U937  HL69  KGI 
% 
Ami-IL2R  +  2.0  1.4  64.0  52.7  37.6  63.3  1.9  1.5  64.2  53.8  37.5  63.7  1.7  1.4  62.9 
HLA-DR+ (9-49)  9.8  19.1  92.4  51.4  76.9  94.8  ND  54.0  75.3  97.1  9.0  19.1  90.3 
MY4  +  10.1  8.2  6.1  65.4  67.2  6.4  ND  ND  66.6  5.4  9.9  8.0  6.0 
PGE~ + rlFN-'y  1,25(OH)~ vitamin  DMSO  cAMP  Retinoic acid 
D3 
U937  HL60  KGI  U937  HL60  KGI  U937  HL60  KG1  U937  HL60  KGI  U937  HL60  KG1 
% 
Anti-lL2R  ÷  30.5  21.1  63.8  9.3  2.7  60.8  1.I  1.2  60.1  2.0  1.9  ND  1.9  1.5 
HLA-DR  + (9-49)  24.9  65.0  ND  38.0  ND  ND  12.7  ND  ND 
MY4  ÷  ND  ND  ND  78.9  ND  ND  40.1  ND  ND 
62.9 
Interferon concentration was 500 U/ml. ND, not done. See text for concentrations used. Recovery of viable dells in each fraction was >75%. 
restricted to monocytic cells under the conditions used in this study, except for 
the myeloblast cell line KG-1. 
IL-2R  expression  on  the  myeloid  cell  lines  U937  and  HL60  was associated 
with  induction  of monocytic  differentiation  as  evidenced  by  the  monocytoid 
morphology,  expression  of the  monocyte  membrane antigen  MY4  (Table  IV). 
Compounds that are known to cause differentiation  of HL60 cells into granulo- 
cyte cells (DMSO and retinoic acid) failed to induce IL-2R on HL60 and U937 
(Table  IV).  Similarly,  granulocytes  (Table  III) and normal or leukemic  myelo- 
blasts (fresh M 1 or M2 AML samples) could not be induced to express IL-2R by 
IFN-7.  However,  more "monocytic" AML samples (M4,  M5) could be induced. 
Further,  IFN-7-induced  IL-2R  expression  of U937  cells was restricted  to cells 
that  became  adherent  during  the  culture  (data  not  shown).  Prostaglandin  E2 
(PGE2), known to inhibit monocyte differentiation and class II antigen expression 
(12) partially inhibited the IFN-~'-induced IL-2R expression on U937 cells (Table 
IV).  However,  other compounds that promote macrophage-like  differentiation 
of U937,  such  as  1,25(OH)2  vitamin  D3,  did  not  cause  IL-2R  expression  on 
U937 cells (Table IV) suggesting a specific role for IFN-~, in inducing IL-2R on 
macrophage-like differentiated cells. 
Since IL-2 induces proliferation  of IL-2R + T  and B cells,  the function of IL- HERRMANN  ET  AL.  BRIEF  DEFINITIVE  REPORT  1115 
FIGURE 2.  Dual color fluorescence analysis of 1L-2R expression on IFN-'r (48 h, 500 U/ml)- 
treated peripheral  blood monocytes.  Mo2 antigen was detected with biotin-conjugated anti- 
Mo2 (x axis), and IL-2R detected with fluorescein IL-2R1 monoclonal antibody (y axis). 
2R on U937 cells was investigated.  IFN treatment of U937 cells induced a dose- 
dependent  inhibition  of [3H]TdR incorporation  as expected.  Addition  of IL-2 
to  IGN-y-treated  U937  cells  modestly  increased  [3H]TdR  incorporation  in  a 
dose-dependent  manner,  but  never  to  greater  than  starting  levels  (data  not 
shown). This IL-2 effect could be blocked by anti-IL-2R antibody. 
IFN-'y-induced IL-2R expression was not restricted to malignant human mon- 
ocytic cells. By one color (Table III) and two color immunofluorescence (Fig. 2) 
normal  peripheral  blood  monocyte  preparations  (99%  pure  as  estimated  by 
morphology and Mo2 staining)  could be induced to express IL-2R by recombi- 
nant IFN-y (99.4% of cells stained by biotinylated Mo2 antibody, 62.5% double 
stained by biotinylated Mo2 and fluoresceinated anti-IL-2R 1). 
These findings reveal a previously unknown function of IFN-3,. The biological 
consequences of IL-2R expression  by normal  monocytes have  not been deter- 
mined,  but  these  results  implicate  the  IL-2/IL-2R  system  in  the  control  of 
macrophage differentiation and/or function.  It is also possible that macrophage 
IL-2R expression adsorbs IL-2 at inflammatory sites, and thus serves as a negative 
feedback loop in T  cell/macrophage interaction. 
Summary 
Gamma interferon induced surface expression of interleukin 2 (IL-2) receptors 
on normal  human  monocytes and  the  monocytoid cell lines  U937 and  HL60. 
These receptors were detected by anti-IL-2 receptor monoclonal antibodies, and 
U937 IL-2 receptors were indistinguishable  from T  lymphocyte IL-2 receptors 
by immunoprecipitation.  Also,  U937  IL-2  receptors  bound biologically active 
IL-2. These results suggest a role for monocyte IL-2 receptors in T  cell/monocyte 
interaction  during an immune response. 
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